Table 4.

Compound potency (μM) in primary screen (Mito-MPS assay), powder compound confirmation (Mito-MPS assay), imaging confirmation, and cytotoxicity assay at 1 and 5 h of treatment

		1 h				5 h
Name	CASRN	Primary Screen	Confirmation	Cytotoxicity	Imaging Confirmation	Primary Screen	Confirmation	Cytotoxicity*	Imaging Confirmation
Apigenin	520-36-5	25.91	7.17 ± 1.34	inactive	4.06	4.60	12.68 ± 3.17	inactive	9.49
BIO	667463-62-9	0.09	0.23 ± 0.06	inactive	1.83	0.23	0.42 ± 0.05	inactive	1.94
Diphenyleneiodonium chloride	4673-26-1	3.26	15.46 ± 5.84	inactive	19.87	1.83	8.05 ± 6.91	inactive	9.74
Genistein	446-72-0	25.91	18.10 ± 4.10	inactive	7.74	7.94	18.76 ± 5.70	inactive	12.27
GW-5074	220904-83-6	7.30	6.43 ± 1.41	inactive	6.52	2.31	5.85 ± 2.07	inactive	7.74
Indirubin-3′-oxime	160807-49-8	0.25	0.44 ± 0.09	inactive	4.38	0.41	0.55 ± 0.12	inactive	4.35
Isoliquiritigenin	961-29-5	6.51	5.87 ± 1.88	inactive	3.88	3.66	10.24 ± 2.53	inactive	12.27
Niclosamide	50-65-7	0.41	0.72 ± 0.50	inactive	0.41	0.32	0.75 ± 0.46	1.12 (48%)	0.52
Piceatannol	10083-24-6	10.31	5.87 ± 1.41	inactive	5.81	5.17	8.64 ± 2.35	inactive	12.27
Rottlerin	82-08-6	6.51	5.65 ± 2.59	inactive	1.54	3.26	4.04 ± 0.82	1.78 (49%)	1.37
SP-600125	129-56-6	1.15	2.50 ± 0.88	inactive	24.64	1.63	2.52 ± 0.31	inactive	27.47
Tyrphostin 47	122520-86-9	12.59	7.38 ± 0.84	inactive	16.39	16.35	21.0 ± 4.15	inactive	54.8
Tyrphostin A9	10537-47-0	0.07	0.15 ± 0.06	inactive	0.07	0.04	0.18 ± 0.08	inactive	0.11
Tyrphostin AG-879	148741-30-4	0.51	2.22 ± 0.99	inactive	1.23	0.73	4.06 ± 1.99	inactive	1.73

BIO, (2′Z,3′E)-6-bromoindirubin-3′-oxime.

^*Efficacies are shown in parentheses.